Terminating its proposed deal with Aurobindo to divest its US generic oral solids and dermatology units to the Indian firm for around $1bn will provide Sandoz with an “opportunity to optimize the US business,” the Novartis subsidiary believes.
At the start of April, the two firms announced the termination of the deal by mutual consent. (Also see "




